Casos Editados SOLACI 2014

Casos editados presentados durante el Congreso SOLACI-CACI ’14. 23 al 25 de Abril de 2014 en Buenos Aires.-

More articles by this author

How to apply for the SOLACI Research 2025 Grant? Step-by-step explanation video

You can now rewatch the virtual event we held on April 9th, where we thoroughly reviewed the steps to apply for the SOLACI Research...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

Watch Angioplasty Techniques for Bifurcations Again From a Completely Different Perspective.

You can now watch on our YouTube channel the event we held in collaboration with Medtronic, titled: "Visualizations of Different PCI Techniques for Bifurcations...

Rewatch our event “The Visible Heart Lab” on coronary bifurcations

You can now watch our event held in collaboration with Medtronic, titled "The Visible Heart Lab – Live Cases on DK Crush and Culotte." The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...